Clinical Trial Update: Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating sacituzumab govitecan in combination with pembrolizumab for resectable non-small cell lung cancer is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (Keytruda) (pembrolizumab)
• Sacituzumab Govitecan (Trodelvy) (sacituzumab govitecan)

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: Lung Cancer | Phase 2 | Status: RECRUITING